ECSP066461A - Método para activar las poblaciones de célula especificas utilizando conjugados maitansinoides del agente de enlace celular enlazados a través de un enlazador no divisible, dichos conjugados, y métodos para hacer dichos conjugados - Google Patents

Método para activar las poblaciones de célula especificas utilizando conjugados maitansinoides del agente de enlace celular enlazados a través de un enlazador no divisible, dichos conjugados, y métodos para hacer dichos conjugados

Info

Publication number
ECSP066461A
ECSP066461A EC2006006461A ECSP066461A ECSP066461A EC SP066461 A ECSP066461 A EC SP066461A EC 2006006461 A EC2006006461 A EC 2006006461A EC SP066461 A ECSP066461 A EC SP066461A EC SP066461 A ECSP066461 A EC SP066461A
Authority
EC
Ecuador
Prior art keywords
conjugates
maitansinoid
methods
make
agent linked
Prior art date
Application number
EC2006006461A
Other languages
English (en)
Spanish (es)
Inventor
Rita Steeves
Robert Lutz
Ravi Chari
Hongsheng Xie
Yelena Kovtun
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34467962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066461(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of ECSP066461A publication Critical patent/ECSP066461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
EC2006006461A 2003-10-10 2006-03-28 Método para activar las poblaciones de célula especificas utilizando conjugados maitansinoides del agente de enlace celular enlazados a través de un enlazador no divisible, dichos conjugados, y métodos para hacer dichos conjugados ECSP066461A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50990103P 2003-10-10 2003-10-10
US10/960,602 US8088387B2 (en) 2003-10-10 2004-10-08 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates

Publications (1)

Publication Number Publication Date
ECSP066461A true ECSP066461A (es) 2007-05-30

Family

ID=34467962

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006461A ECSP066461A (es) 2003-10-10 2006-03-28 Método para activar las poblaciones de célula especificas utilizando conjugados maitansinoides del agente de enlace celular enlazados a través de un enlazador no divisible, dichos conjugados, y métodos para hacer dichos conjugados

Country Status (26)

Country Link
US (10) US8088387B2 (en:Method)
EP (4) EP2596804A3 (en:Method)
JP (10) JP2007520450A (en:Method)
KR (4) KR101476082B1 (en:Method)
CN (3) CN108578710B (en:Method)
AU (2) AU2004282491C1 (en:Method)
BE (1) BE2013C075I2 (en:Method)
BR (1) BRPI0415448A8 (en:Method)
CA (3) CA3139478A1 (en:Method)
CY (2) CY1113984T1 (en:Method)
DK (1) DK1689846T3 (en:Method)
EA (1) EA010508B1 (en:Method)
EC (1) ECSP066461A (en:Method)
ES (1) ES2404304T3 (en:Method)
FR (1) FR13C0068I2 (en:Method)
HK (1) HK1244452A1 (en:Method)
HR (1) HRP20130412T1 (en:Method)
HU (1) HUS1300075I1 (en:Method)
IL (4) IL173625A (en:Method)
LU (1) LU92336I2 (en:Method)
NO (2) NO337458B1 (en:Method)
NZ (2) NZ545195A (en:Method)
PL (1) PL1689846T3 (en:Method)
PT (1) PT1689846E (en:Method)
SI (1) SI1689846T1 (en:Method)
WO (1) WO2005037992A2 (en:Method)

Families Citing this family (325)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
PT2163256E (pt) 2001-05-11 2015-11-20 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
CN100422316C (zh) * 2002-05-24 2008-10-01 先灵公司 抗胰岛素样生长因子受体(igfr)的人源中和抗体
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005082023A2 (en) * 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
RU2404810C9 (ru) * 2004-06-01 2015-06-20 Дженентек, Инк. Конъюгаты антитело-лекарственное средство и способы
AU2004224925C1 (en) * 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
CN104447992A (zh) 2004-09-23 2015-03-25 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
ES2503719T3 (es) 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
WO2006113483A2 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
ES2533992T3 (es) 2005-08-24 2015-04-16 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpo maitansinoide
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2007100385A2 (en) * 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
US8197815B2 (en) 2006-01-20 2012-06-12 Genentech, Inc. Anti-EphrinB2 antibodies and methods using same
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
US8524865B2 (en) 2006-05-30 2013-09-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2008052187A2 (en) 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
CN101711284A (zh) 2007-01-25 2010-05-19 达娜-法勃肿瘤研究所 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
MX2009009782A (es) 2007-03-15 2010-09-10 Ludwig Inst Cancer Res Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
KR101540822B1 (ko) 2007-03-27 2015-07-30 씨 레인 바이오테크놀로지스, 엘엘씨 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
RU2511410C3 (ru) * 2007-07-16 2021-06-15 Дженентек, Инк. АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
PE20090481A1 (es) 2007-07-16 2009-05-18 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
HUE047200T2 (hu) 2007-08-17 2020-04-28 Purdue Research Foundation PSMA kötõ ligandum-linker konjugátumok és azok alkalmazási módszerei
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
PE20140853A1 (es) 2008-01-31 2014-08-04 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
KR20190077616A (ko) 2008-03-18 2019-07-03 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
US20100092495A1 (en) * 2008-04-30 2010-04-15 Immunogen Inc. Potent cell-binding agent drug conjugates
WO2009134870A1 (en) * 2008-04-30 2009-11-05 Immunogen, Inc. Potent cell-binding agent drug conjugates
BRPI0910746B8 (pt) * 2008-04-30 2021-05-25 Immunogen Inc agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica
EP2276506A4 (en) * 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
EP3100745B1 (en) 2009-02-05 2018-04-18 Immunogen, Inc. Novel benzodiazepine derivatives
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
JP6132548B2 (ja) 2009-04-01 2017-05-24 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５抗体および免疫接合体および使用方法
AU2010230563A1 (en) 2009-04-02 2011-09-22 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain Fab fragments
JP5863640B2 (ja) 2009-04-29 2016-02-16 バイオ−ラッド ラボラトリーズ インコーポレーティッド 免疫複合体の精製
JP2012526839A (ja) 2009-05-13 2012-11-01 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和分子
KR102444399B1 (ko) 2009-06-03 2022-09-16 이뮤노젠 아이엔씨 메이탄시노이드의 제조방법
CA2763935A1 (en) 2009-06-04 2010-12-09 Novartis Ag Methods for identification of sites for igg conjugation
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011031870A1 (en) * 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
JP2013506709A (ja) * 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
MX343328B (es) * 2009-10-26 2016-11-01 Nestec Sa Analisis para la deteccion de farmacos anti-tnf y anticuerpos.
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
US20110165155A1 (en) * 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
MX2012007379A (es) 2009-12-23 2012-08-31 Genentech Inc Anticuerpos anti-bv8 y usos de los mismos.
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
RU2595389C2 (ru) 2010-02-23 2016-08-27 Дженентек, Инк. Композиции и способы для диагностики и лечения опухолей
TWI781327B (zh) 2010-02-24 2022-10-21 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
MX338932B (es) 2010-03-12 2016-05-06 Immunogen Inc Moleculas de union cd37 y sus inmunoconjugados.
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
TWI586806B (zh) 2010-04-23 2017-06-11 建南德克公司 異多聚體蛋白質之製造
RU2613886C2 (ru) 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
KR101839163B1 (ko) 2010-06-08 2018-03-15 제넨테크, 인크. 시스테인 조작된 항체 및 접합체
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
EP2632947A4 (en) * 2010-10-29 2015-03-18 Immunogen Inc NON-ANTAGONIST MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
US8790649B2 (en) 2010-10-29 2014-07-29 Immunogen, Inc. EGFR-binding molecules and immunoconjugates thereof
US20120121615A1 (en) * 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
ES2860748T3 (es) 2011-01-24 2021-10-05 Gilead Sciences Inc Anticuerpos selectivos para células que presentan EGFR con alta densidad
EP2670776B1 (en) 2011-02-04 2018-11-21 F. Hoffmann-La Roche AG Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
KR20200140939A (ko) 2011-02-15 2020-12-16 이뮤노젠 아이엔씨 컨쥬게이트의 제조방법
WO2012135522A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
AU2012236403B2 (en) * 2011-03-29 2016-08-04 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
SI2691155T1 (sl) 2011-03-29 2019-03-29 Immunogen, Inc. Priprava majtanzinoidnih konjugatov protiteles v postopku z enim korakom
US9447189B2 (en) 2011-04-01 2016-09-20 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
KR101982317B1 (ko) 2011-04-01 2019-05-27 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
JP2014513692A (ja) 2011-05-09 2014-06-05 ユニバーシティ オブ バージニア パテント ファウンデーション 癌を治療するための組成物及び方法
ES2704038T3 (es) 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US8685383B2 (en) 2011-06-10 2014-04-01 Mersana Therapeautics, Inc. Protein-polymer-drug conjugates
EP2723389A2 (en) 2011-06-21 2014-04-30 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
EP2736928B1 (en) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
SG10201800158XA (en) 2011-09-22 2018-02-27 Amgen Inc Cd27l antigen binding proteins
WO2013049521A2 (en) * 2011-09-29 2013-04-04 Virginia Commonwealth University Light-enabled drug delivery
AU2012328980A1 (en) 2011-10-28 2014-04-24 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
AP2014007638A0 (en) 2011-11-16 2014-05-31 Amgen Inc Methods of treating epidermal growth factor deletion mutant VIII related disorders
BR112014012155A2 (pt) 2011-11-21 2017-05-30 Immunogen Inc método de tratamento de tumores que são resistentes a terapias de egfr por conjugado de agente citotóxico de anticorpo egfr
CA2858133A1 (en) 2011-12-08 2013-06-13 Biotest Ag Uses of immunoconjugates targeting cd138
ES2710916T3 (es) 2011-12-22 2019-04-29 I2 Pharmaceuticals Inc Proteínas de unión sustitutas
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
AU2013209512B2 (en) 2012-01-20 2017-08-03 I2 Pharmaceuticals, Inc. Surrobody cojugates
CN104105711B (zh) 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 单链抗体及其他异多聚体
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
KR20150003251A (ko) * 2012-04-04 2015-01-08 가부시키가이샤 페르세우스 프로테오믹스 항 cdh3(p-카드헤린) 항체의 약물 콘쥬게이트
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
MX2014013041A (es) * 2012-04-27 2015-03-19 Cytomx Therapeutics Inc Anticuerpos activables que se ligan al receptor del factor de crecimiento epidermico y metodos de uso de los mismos.
JP6242865B2 (ja) 2012-05-01 2017-12-06 ジェネンテック， インコーポレイテッド 抗ｐｍｅｌ１７抗体および免疫複合体
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
EP3520817A1 (en) * 2012-05-15 2019-08-07 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
JP6423340B2 (ja) 2012-05-15 2018-11-14 シアトル ジェネティクス，インコーポレイティド 自己安定化リンカー結合体
BR112014028366A2 (pt) 2012-05-21 2017-06-27 Genentech Inc anticorpos anti-ly6e e imunoconjugados e métodos de uso
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
HK1207864A1 (en) 2012-06-27 2016-02-12 F. Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
EP2879708A4 (en) 2012-08-02 2016-03-16 Genentech Inc ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES
MX2015001407A (es) 2012-08-02 2015-05-08 Genentech Inc Inmunoconjugados y anticuerpos anti-etbr.
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
RS58493B1 (sr) 2012-09-26 2019-04-30 Immunogen Inc Poboljšani postupak za acilaciju majtanzinola
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
MY171561A (en) 2012-11-15 2019-10-18 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN103333246B (zh) * 2012-12-21 2015-09-16 百奥泰生物科技(广州)有限公司 一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途
CN103333179B (zh) * 2012-12-21 2017-06-16 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9498532B2 (en) * 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US10150813B2 (en) 2013-03-14 2018-12-11 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CN105188766B (zh) 2013-03-15 2019-07-12 瑞泽恩制药公司 生物活性分子、其偶联物及治疗用途
US9498543B2 (en) * 2013-03-15 2016-11-22 Novartis Ag Antibody drug conjugates
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
EP2976362B1 (en) 2013-03-19 2019-10-23 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP6660294B2 (ja) 2013-06-04 2020-03-11 シトムクス セラピューティクス，インコーポレイティド 活性化可能抗体を結合するための組成物及び方法
AU2014299561B2 (en) 2013-06-24 2017-06-08 Ablbio Antibody-drug conjugate having improved stability and use thereof
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
EP3016980B1 (en) 2013-07-05 2020-05-06 Formation Biologics Inc. Egfr antibody conjugates
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
RU2560699C2 (ru) * 2013-08-02 2015-08-20 федеральное государственное автономное образовательное учреждение высшего профессионального образования "Национальный исследовательский ядерный университет МИФИ" (НИЯУ МИФИ) Способ создания наноразмерной диагностической метки на основе конъюгатов наночастиц и однодоменных антител
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
WO2015031396A1 (en) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
KR102310441B1 (ko) 2013-09-05 2021-10-07 더 잭슨 래보라토리 Rna-염색질 상호작용 분석용 조성물 및 이의 용도
EP3041484B1 (en) 2013-09-06 2021-03-03 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
HK1218124A1 (zh) 2013-09-17 2017-02-03 豪夫迈．罗氏有限公司 使用抗lgr5抗体的方法
WO2015054400A2 (en) 2013-10-08 2015-04-16 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
EP3054991B1 (en) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2927022C (en) 2013-10-11 2018-08-21 Asana Biosciences, Llc Protein-polymer-drug conjugates
SG11201600954XA (en) 2013-10-15 2016-03-30 Seattle Genetics Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US10836821B2 (en) 2013-10-15 2020-11-17 Sorrento Therapeutics, Inc. Drug-conjugates with a targeting molecule and two different drugs
GEP20217330B (en) 2013-10-18 2021-12-10 Ruprecht Karls Univ Heidelberg De Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3060253B1 (en) 2013-10-21 2018-12-19 Genentech, Inc. Anti-ly6e antibodies and methods of use
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CN105940113A (zh) 2013-11-13 2016-09-14 酵活有限公司 靶向egfr和/或her2的单价抗原结合构建体及其用途
SG10201803618RA (en) 2013-11-14 2018-06-28 Endocyte Inc Compounds for positron emission tomography
RS66775B1 (sr) 2013-11-27 2025-05-30 Zymeworks Bc Inc Bispecifični antigen-vezujući konstrukti koji targetiraju her2
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
PT3082878T (pt) 2013-12-19 2022-11-30 Seagen Inc Ligantes de carbamato de metileno para uso com conjugados de fármacos de marcação
US9943606B2 (en) 2014-01-15 2018-04-17 Rutgers, The State University Of New Jersey Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
EP3095462B1 (en) 2014-01-15 2019-08-14 Order-Made Medical Research Inc. Therapeutic pharmaceutical composition employing anti-slc6a6 antibody
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
RU2669807C2 (ru) 2014-01-27 2018-10-16 Пфайзер Инк. Бифункциональные цитотоксические агенты
MX2016009332A (es) * 2014-01-29 2016-12-20 Shanghai hengrui pharmaceutical co ltd Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo.
MX2016010295A (es) 2014-02-11 2016-10-17 Seattle Genetics Inc Reduccion selectiva de proteinas.
CN106414465B (zh) 2014-02-28 2021-11-16 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
TWI687428B (zh) 2014-03-27 2020-03-11 中央研究院 反應性標記化合物及其用途
JP6715186B2 (ja) 2014-05-06 2020-07-01 ジェネンテック， インコーポレイテッド 哺乳動物細胞を用いたヘテロ多量体タンパク質の生成
KR102821413B1 (ko) 2014-05-27 2025-06-17 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267047A1 (en) 2014-05-27 2017-01-05 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
CA2950433A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
EP3682904A1 (en) 2014-06-30 2020-07-22 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
SG11201610880RA (en) 2014-06-30 2017-01-27 Tarveda Therapeutics Inc Targeted conjugates and particles and formulations thereof
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
KR20170040249A (ko) 2014-08-12 2017-04-12 노파르티스 아게 항-cdh6 항체 약물 접합체
KR20240011258A (ko) 2014-09-02 2024-01-25 이뮤노젠 아이엔씨 항체 약물 컨쥬게이트 조성물의 제형화 방법
HUE051002T2 (hu) 2014-09-03 2021-01-28 Immunogen Inc Citotoxikus benzodiazepin származékok
EP3189057A1 (en) 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
HRP20241124T1 (hr) 2014-09-11 2024-11-22 Seagen Inc. Ciljana isporuka lijekovitih tvari koje sadrže tercijarni amin
AR101844A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos y conjugados modificados genéticamente con cisteína
US10059768B2 (en) 2014-09-12 2018-08-28 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
HUE049175T2 (hu) 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
AU2015319809B2 (en) 2014-09-28 2020-02-06 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
CN106794259B (zh) 2014-10-14 2021-07-16 宝力泰锐克斯有限公司 采用包含含有peg部分的离去基团的试剂缀合肽或蛋白质的方法
JP6831783B2 (ja) 2014-11-14 2021-02-17 ノバルティス アーゲー 抗体薬物コンジュゲート
US20170355779A1 (en) 2014-11-27 2017-12-14 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
BR112017011773A2 (pt) 2014-12-04 2018-02-20 Celgene Corporation composto isolado, conjugados isolados, composiçôes farmacêuticas, e métodos de tratamento de um distúrbio em um mamífero
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3248005B1 (en) 2015-01-24 2020-12-09 Academia Sinica Novel glycan conjugates and methods of use thereof
JP6871858B2 (ja) 2015-01-28 2021-05-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート
SG11201706991YA (en) 2015-03-20 2017-10-30 Pfizer Bifunctional cytotoxic agents containing the cti pharmacophore
KR102708103B1 (ko) 2015-03-27 2024-09-20 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
CN116063543A (zh) 2015-04-24 2023-05-05 豪夫迈·罗氏有限公司 多特异性抗原结合蛋白
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
MX392539B (es) 2015-06-08 2025-03-24 Debiopharm Int Sa Combinaciones de inmunoconjugado anti-cd37 y anticuerpo anti-cd20.
EP3308801A4 (en) * 2015-06-09 2019-02-27 XDCExplorer (Shanghai) Co., Ltd. ANTIBODY-ACTIVE CONJUGATE, INTERMEDIATE PRODUCT, METHOD OF MANUFACTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
CA2988806A1 (en) 2015-06-29 2017-01-05 Immunogen, Inc. Conjugates of cysteine engineered antibodies
CN107708676A (zh) * 2015-06-30 2018-02-16 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
CN113350518A (zh) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
ES2820358T3 (es) 2015-07-21 2021-04-20 Immunogen Inc Métodos de preparación de derivados de benzodiazepina citotóxicos
EP3331569A1 (en) 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
KR102766022B1 (ko) 2015-08-28 2025-02-10 데비오팜 인터네셔날 에스 에이 Cd37 의 검출을 위한 항체 및 검정
CN108348604B (zh) * 2015-09-08 2022-04-29 沃特世科技公司 用于分析抗体-药物缀合物的多维色谱方法
US10172875B2 (en) 2015-09-17 2019-01-08 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
MX2018004285A (es) 2015-10-08 2018-11-09 Zymeworks Inc Construcciones polipeptidicas de union al antigeno que comprenden cadenas ligeras kappa y lambda y usos de estas.
CA3001712A1 (en) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof
DK3380525T3 (da) 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017096311A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugates of quaternized tubulysin compounds
CN108779127B (zh) 2016-01-25 2022-07-05 里珍纳龙药品有限公司 美登素类化合物衍生物、其偶联物和使用方法
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド 突然変異体スムースンド及びその使用方法
PH12018501638B1 (en) 2016-02-04 2022-11-04 Hangzhou Dac Biotech Co Ltd Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
US10548881B2 (en) 2016-02-23 2020-02-04 Tarveda Therapeutics, Inc. HSP90 targeted conjugates and particles and formulations thereof
AU2017231749A1 (en) 2016-03-08 2018-09-20 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
EA201892040A1 (ru) 2016-03-25 2019-04-30 Сиэтл Дженетикс, Инк. Способ получения пегилированных соединений лекарственный препарат - линкер и их промежуточных соединений
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
CN115317603A (zh) 2016-07-07 2022-11-11 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
SG11201900699QA (en) 2016-08-09 2019-02-27 Seattle Genetics Inc Drug conjugates with self-stabilizing linkers having improved physiochemical properties
US9950070B2 (en) * 2016-08-16 2018-04-24 Korea University Research And Business Foundation HER2 aptamer-anticancer drug complex for cancer cell chemotherapy
KR102588027B1 (ko) 2016-08-22 2023-10-12 초 파마 인크. 항체, 결합 단편 및 사용 방법
TWI835714B (zh) 2016-10-18 2024-03-21 美商思進公司 菸鹼醯胺腺嘌呤二核苷酸補救合成(salvage pathway)抑制劑之靶向投遞
US20180118811A1 (en) 2016-10-19 2018-05-03 Invenra Inc. Antibody constructs
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
WO2018086139A1 (en) 2016-11-14 2018-05-17 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
EP3544983A2 (en) 2016-11-23 2019-10-02 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
EP3548514A1 (en) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CA3047115A1 (en) 2016-12-16 2018-06-21 Bluefin Biomedicine, Inc. Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
AU2017383142A1 (en) 2016-12-22 2019-07-04 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43
HUE058664T2 (hu) 2016-12-23 2022-09-28 Immunogen Inc ADAM9-et célzó immunkonjugátumok és eljárások azok felhasználására
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CN116785451A (zh) 2017-02-28 2023-09-22 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
TW201839001A (zh) 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
US20180311375A1 (en) * 2017-04-27 2018-11-01 Cadila Healthcare Limited Process of preparing antibody-drug conjugate
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
JP7245793B2 (ja) 2017-06-30 2023-03-24 ザイムワークス ビーシー インコーポレイテッド 安定化したキメラＦａｂ
CA3074111A1 (en) 2017-08-28 2019-03-07 Angiex, Inc. Anti-tm4sf1 antibodies and methods of using same
JP7185696B2 (ja) 2017-09-22 2022-12-07 ウーシー バイオロジクス アイルランド リミテッド 新規な二重特異性ｃｄ３／ｃｄ１９ポリペプチド複合体相互参照
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
EA202090947A1 (ru) 2017-11-29 2020-08-26 Маджента Терапьютикс, Инк. Композиции и способы для истощения cd5+ клеток
US11793885B2 (en) 2017-12-28 2023-10-24 Immunogen, Inc. Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders
WO2019150985A1 (ja) * 2018-01-31 2019-08-08 国立大学法人東京大学 抗体薬物複合体及びそれを含む医薬組成物
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
CN112040981A (zh) 2018-04-13 2020-12-04 基因泰克公司 稳定的抗cd79b免疫缀合物制剂
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
CA3101790A1 (en) 2018-05-30 2019-12-05 Debiopharm International, S.A. Anti-cd37 immunoconjugate dosing regimens
JP7653260B2 (ja) 2018-06-05 2025-03-28 キングス・カレッジ・ロンドン 消化管系へのペイロード送達のための、ｂｔｎｌ３／８を標的とする構築物
CA3104511A1 (en) 2018-06-26 2020-01-02 Immunogen, Inc. Immunoconjugates targeting adam9 and methods of use thereof
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
JP2021532116A (ja) 2018-07-23 2021-11-25 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
US20210283269A1 (en) 2018-07-25 2021-09-16 Daiichi Sankyo Company, Limited Effective method for manufacturing antibody-drug conjugate
BR112021004656A2 (pt) 2018-09-26 2021-06-01 Jiangsu Hengrui Medicine Co., Ltd. conjugado fármaco-ligante de análogo exatecano, método para preparar o mesmo e aplicação do mesmo
TW202029980A (zh) 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
CN113993549A (zh) 2019-03-15 2022-01-28 博尔特生物治疗药物有限公司 靶向her2的免疫缀合物
SG11202109066RA (en) 2019-03-19 2021-09-29 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
HUE070544T2 (hu) 2019-03-20 2025-06-28 Univ California Klaudin-6-ellenanyagok és hatóanyag-konjugátumok
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
JP2022529583A (ja) 2019-03-29 2022-06-23 イミュノジェン・インコーポレーテッド 異常細胞増殖を阻害するまたは増殖性疾患を治療するための細胞毒性ビス－ベンゾジアゼピン誘導体及び細胞結合剤とのその複合体
AU2020263959A1 (en) 2019-04-24 2021-11-25 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
IL286846B2 (en) 2019-04-26 2025-06-01 Immunogen Inc Camptothecin derivatives
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
EP3996749A1 (en) 2019-07-10 2022-05-18 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
EP4032892A4 (en) 2019-09-18 2023-10-18 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin derivative and conjugate thereof
CN114450324B (zh) 2019-09-26 2024-02-27 日油株式会社 具有肽连接子的异双官能单分散聚乙二醇
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN115322794A (zh) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
KR20220130160A (ko) 2020-01-22 2022-09-26 상하이 센후이 메디슨 컴퍼니 리미티드 에리불린 유도체의 약물 접합체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도
WO2021173773A1 (en) 2020-02-25 2021-09-02 Mediboston, Inc. Camptothecin derivatives and conjugates thereof
CN111195353B (zh) * 2020-03-19 2023-06-23 烟台迈百瑞国际生物医药股份有限公司 一种美登素类抗体药物偶联物及其应用
WO2021190602A1 (zh) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
US20230165969A1 (en) 2020-03-25 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising antibody drug conjugate and use thereof
CA3176248A1 (en) 2020-04-10 2021-10-14 Seagen Inc. Charge variant linkers
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
JP7717832B2 (ja) 2021-04-10 2025-08-04 ジェンマブ エー／エス Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
WO2022226317A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023092099A1 (en) 2021-11-19 2023-05-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
WO2023157989A1 (ko) 2022-02-17 2023-08-24 주식회사 노벨티노빌리티 항체-약물 접합체
CR20240415A (es) 2022-03-09 2024-11-07 Astrazeneca Ab MOLÉCULAS DE UNIÓN CONTRA FRa
WO2023170216A1 (en) 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
TW202412762A (zh) 2022-07-27 2024-04-01 香港商祐方有限公司 奧瑞他汀衍生物及其結合物
AU2023370106A1 (en) 2022-10-25 2025-05-08 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy for the treatment of cancer
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)
TW202434311A (zh) 2023-02-09 2024-09-01 英屬開曼群島商百濟神州有限公司 自穩定連接子軛合物
WO2024170660A1 (en) 2023-02-16 2024-08-22 Astrazeneca Ab Combination therapies for treatment of cancer with therapeutic binding molecules
TW202438114A (zh) 2023-03-23 2024-10-01 瑞士商百濟神州瑞士有限責任公司 生物活性結合物、其製備方法及其用途
WO2024246657A1 (en) * 2023-05-29 2024-12-05 Intas Pharmaceuticals Ltd. Method for conjugation and purification of antibody drug conjugate
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
WO2024251846A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with mek inhibitors for the treatment of cancer
WO2024251854A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
GB1603640A (en) 1977-07-20 1981-11-25 Gist Brocades Nv Enzyme particles
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPS58167592A (ja) 1982-03-26 1983-10-03 Takeda Chem Ind Ltd 新規メイタンシノイド化合物
LU86212A1 (fr) 1985-12-16 1987-07-24 Omnichem Sa Nouveaux conjugues de la vinblastine et de ses derives,procede pour leur preparation et compositions pharmaceutiques les contenant
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5395924A (en) 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
JPS6484959A (en) 1987-09-25 1989-03-30 Nec Corp System for connecting test line
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
FR2656555B1 (fr) * 1989-12-29 1994-10-28 Serimer Systeme mecanique de guidage automatique d'une ou plusieurs torches d'une unite de soudage a l'arc.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
EP0656367A1 (en) 1991-08-22 1995-06-07 Becton, Dickinson and Company Method and composition for cancer therapy and for prognosticating responses to cancer theraphy
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US7754211B2 (en) 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
JP2861631B2 (ja) 1992-05-06 1999-02-24 日本電気株式会社 Ｆｓｋ受信機
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
CA2120745A1 (en) 1992-06-30 1994-01-06 Philip G. Kasprzyk A combination of anti-erbb-2 monoclonal antibodies and method of using
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994022478A1 (en) 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
JPH10510146A (ja) 1994-11-21 1998-10-06 ザ ユニバーシティ オブ リーズ 改変されたプロテイナーゼインヒビター
US5679648A (en) 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
US5614692A (en) 1995-06-30 1997-03-25 Tracor Aerospace, Inc. Shaped-charge device with progressive inward collapsing jet
NZ500539A (en) 1995-07-27 2001-11-30 Genentech Inc An antibody that binds HER2 receptor in a composition for treating endometrial, lung, colon or bladder cancer
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
KR100473278B1 (ko) 1996-05-23 2005-08-29 켈빈 윈스턴 던컨 식물체로부터프로안토시아니딘을추출및단리시키는방법
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
CA2263420A1 (en) 1996-08-30 1998-03-05 James Edward Ray Pharmaceutical compounds
JPH1084959A (ja) * 1996-09-06 1998-04-07 Nobuyoshi Shimizu 細胞表面レセプターに対するモノクローナル抗体ならびにそのフラグメントの結合体ならびに複合体、それらの製法ならびに細胞への嵌入方法および使用方法
NZ334883A (en) * 1996-09-20 2000-09-29 Meiji Seika Kaisha A crystalline substance of cefditoren pivoxil which has desirable thermal storage stability and the production of the same
AU4982097A (en) 1996-10-18 1998-05-15 Board Of Regents, The University Of Texas System Anti-erbb2 antibodies
DE69735112T2 (de) 1996-11-06 2006-09-07 Sequenom, Inc., San Diego Verfahren zur Analyse und Vorrichtung
CA2274641A1 (en) 1996-12-12 1998-06-18 David Richard Corbin Improved packaging composition
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
JP2002501721A (ja) 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ATE406441T1 (de) 1997-10-29 2008-09-15 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6914130B2 (en) 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
WO2000020579A1 (en) 1998-10-02 2000-04-13 Mcmaster University Spliced form of erbb-2/neu oncogene
ATE296839T1 (de) 1999-03-01 2005-06-15 Genentech Inc Antikörper zur krebsbehandlung und -diagnose
DK2266537T3 (en) 1999-04-01 2014-12-15 Talon Therapeutics Inc Compositions for treating cancer
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
HUP0201009A2 (en) 1999-05-07 2002-07-29 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
JP2004506533A (ja) 1999-05-12 2004-03-04 アレイ　アクチボラゲット クリーニングユニットを備えた直接印刷装置
DE60040981D1 (de) 1999-05-14 2009-01-15 Genentech Inc BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
JP4283474B2 (ja) 1999-06-25 2009-06-24 ジェネンテック・インコーポレーテッド ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療
CA2383493C (en) 1999-06-25 2010-08-10 Genentech, Inc. Treating prostate cancer with anti-erbb2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CN100482281C (zh) 1999-06-25 2009-04-29 基因技术股份有限公司 抗ErbB抗体-类美坦素偶联物在制备药物中的应用
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6362342B1 (en) 1999-06-29 2002-03-26 Lion Bioscience Ag Triazole compounds and methods of making same
CA2379274A1 (en) 1999-07-12 2001-01-18 Genentech, Inc. Blocking immune response to a foreign antigen using an antagonist which binds to cd20
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
KR20020027587A (ko) 1999-08-27 2002-04-13 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
US7303749B1 (en) * 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
BE1012928A6 (nl) 1999-10-07 2001-06-05 Hoeberigs Jean Marie Mathieu Cilinderoven voor verwarming van frites met hete lucht.
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
DK1226177T3 (da) 1999-10-29 2008-10-06 Genentech Inc Antistofsammensætninger mod anti-prostata stamcelle-antigen (PSCA) og anvendelser deraf
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
NZ520482A (en) * 2000-02-11 2004-12-24 Lilly Co Eli Selective N-acylation of A82846 glycopeptide analogs that are ueful for treating staphylococcal infection
KR20020082227A (ko) 2000-02-24 2002-10-30 제넨테크, 인크. 카스파제 활성화 전구약물 요법
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
WO2002013843A2 (en) 2000-08-17 2002-02-21 University Of British Columbia Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
US6596503B1 (en) 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
CA2420140A1 (en) 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1354896B1 (en) 2000-12-28 2010-02-10 Kyowa Hakko Kirin Co., Ltd. Monoclonal antibody directed against the human bst2 antigen
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2003000113A2 (en) 2001-06-20 2003-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ531515A (en) * 2001-09-05 2007-11-30 Genentech Inc Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20080085283A1 (en) 2001-09-05 2008-04-10 Levinson Arthur D Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20040235068A1 (en) 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20030109682A1 (en) * 2001-09-07 2003-06-12 Daniel Santi Maytansines and maytansine conjugates
MXPA04002593A (es) 2001-09-18 2004-05-31 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumor.
WO2004016225A2 (en) 2002-08-19 2004-02-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
WO2003057163A2 (en) 2002-01-03 2003-07-17 Smithkline Beecham Corporation Methods for preparing immunoconjugates
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
WO2004005470A2 (en) 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
ES2361739T3 (es) * 2002-08-16 2011-06-21 Immunogen, Inc. Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña.
CA2525553C (en) * 2003-05-14 2011-07-05 Immunogen, Inc. Maytansinoid-antibody conjugate compositions
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
NZ612796A (en) 2003-07-21 2015-02-27 Immunogen Inc A ca6 antigen-specific cytotoxic conjugate and methods of using the same
US7754441B2 (en) 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
JP3991983B2 (ja) 2003-12-19 2007-10-17 日産自動車株式会社 車両の駆動制御装置
AU2004308972C1 (en) 2003-12-24 2009-11-26 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
RU2404810C9 (ru) 2004-06-01 2015-06-20 Дженентек, Инк. Конъюгаты антитело-лекарственное средство и способы
CN104447992A (zh) 2004-09-23 2015-03-25 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
CN101948541B (zh) 2005-06-20 2014-08-06 健泰科生物技术公司 用于肿瘤诊断和治疗的组合物和方法
US7195520B1 (en) 2006-07-18 2007-03-27 Chung-Chuan Huang Connector for antenna
KR20190077616A (ko) 2008-03-18 2019-07-03 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
BRPI0910746B8 (pt) * 2008-04-30 2021-05-25 Immunogen Inc agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
MX338932B (es) 2010-03-12 2016-05-06 Immunogen Inc Moleculas de union cd37 y sus inmunoconjugados.
AU2011338383A1 (en) 2010-12-09 2012-06-14 Genentech, Inc. Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1

Also Published As

Publication number Publication date
IL214788A0 (en) 2011-11-30
JP2017200934A (ja) 2017-11-09
JP2007520450A (ja) 2007-07-26
BRPI0415448A (pt) 2006-12-05
NO2016001I1 (no) 2016-01-26
KR20120034800A (ko) 2012-04-12
JP2019142864A (ja) 2019-08-29
HK1244452A1 (zh) 2018-08-10
AU2010212291C1 (en) 2012-11-29
LU92336I2 (fr) 2014-02-17
PL1689846T3 (pl) 2013-07-31
NZ583844A (en) 2011-06-30
EP1689846A2 (en) 2006-08-16
US8563509B2 (en) 2013-10-22
CA2542128C (en) 2022-01-11
JP5926759B2 (ja) 2016-05-25
BE2013C075I2 (en:Method) 2023-12-18
HUS1300075I1 (hu) 2014-02-28
EA010508B1 (ru) 2008-10-30
JP2022068295A (ja) 2022-05-09
AU2010212291B2 (en) 2012-05-24
LU92336I9 (en:Method) 2019-01-16
US8088387B2 (en) 2012-01-03
US20050169933A1 (en) 2005-08-04
HRP20130412T1 (en) 2013-06-30
CY2014002I1 (el) 2020-05-29
US20110281856A1 (en) 2011-11-17
US20210261683A1 (en) 2021-08-26
CA3237922A1 (en) 2005-04-28
JP2020189854A (ja) 2020-11-26
JP2014177463A (ja) 2014-09-25
CN107198778A (zh) 2017-09-26
CA2542128A1 (en) 2005-04-28
US20080171856A1 (en) 2008-07-17
EP1689846B1 (en) 2013-03-27
EP2596803A2 (en) 2013-05-29
JP2016135786A (ja) 2016-07-28
US8198417B2 (en) 2012-06-12
CN108578710B (zh) 2021-11-19
WO2005037992A3 (en) 2009-04-23
EP2596804A2 (en) 2013-05-29
IL173625A0 (en) 2006-07-05
AU2004282491A1 (en) 2005-04-28
KR101476082B1 (ko) 2014-12-23
WO2005037992A2 (en) 2005-04-28
CY2014002I2 (el) 2020-05-29
US20140154804A1 (en) 2014-06-05
US7989598B2 (en) 2011-08-02
KR101343676B1 (ko) 2013-12-20
CY1113984T1 (el) 2016-07-27
ES2404304T3 (es) 2013-05-27
EP2596803A3 (en) 2013-09-11
KR101573124B1 (ko) 2015-12-01
AU2010212291A1 (en) 2010-09-02
EP2596804A3 (en) 2013-09-18
EP1689846A4 (en) 2010-08-04
FR13C0068I2 (fr) 2014-04-11
JP2019011363A (ja) 2019-01-24
US10844135B2 (en) 2020-11-24
US20080171865A1 (en) 2008-07-17
US8163888B2 (en) 2012-04-24
NO2016001I2 (no) 2016-01-26
CA3139478A1 (en) 2005-04-28
EA200600752A1 (ru) 2007-08-31
FR13C0068I1 (en:Method) 2014-01-17
AU2004282491C1 (en) 2011-06-30
US20080145374A1 (en) 2008-06-19
DK1689846T3 (da) 2013-05-06
CN108578710A (zh) 2018-09-28
US20080114153A1 (en) 2008-05-15
NZ545195A (en) 2010-07-30
JP2012006928A (ja) 2012-01-12
US20170226220A1 (en) 2017-08-10
IL246605A (en) 2017-08-31
EP2612682A3 (en) 2013-09-25
AU2004282491B2 (en) 2010-12-23
US20120226025A1 (en) 2012-09-06
JP2024059792A (ja) 2024-05-01
SI1689846T1 (en) 2013-06-28
EP2612682A2 (en) 2013-07-10
IL235253B (en) 2018-04-30
NO20061772L (no) 2006-04-21
PT1689846E (pt) 2013-05-08
CN103223174A (zh) 2013-07-31
KR20140033003A (ko) 2014-03-17
JP5718745B2 (ja) 2015-05-13
BRPI0415448A8 (pt) 2019-08-13
KR20060130552A (ko) 2006-12-19
KR20130102649A (ko) 2013-09-17
IL173625A (en) 2016-07-31
US8685920B2 (en) 2014-04-01
NO337458B1 (no) 2016-04-18

Similar Documents

Publication Publication Date Title
ECSP066461A (es) Método para activar las poblaciones de célula especificas utilizando conjugados maitansinoides del agente de enlace celular enlazados a través de un enlazador no divisible, dichos conjugados, y métodos para hacer dichos conjugados
CY1117721T1 (el) Κυτταρα προελευσης αμνιακου υγρου
AR069980A1 (es) Inmunoconjugados dirigidos contra cd 138 y sus usos
AR069747A1 (es) Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
EA200702575A1 (ru) Иммуногенная композиция
ES2190727B1 (es) Dispositivo para formar y/o aumentar el numero relativo de celulas indiferenciadas en una poblacion celular y procedimientos correspondientes.
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
EP2046735A4 (en) SUBSTITUTED PHENYL SULFUR TRIFLUORIDE AND OTHER SIMILAR FLUORINATING SUBSTANCES
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
BRPI9910394B8 (pt) molÉculas de ligaÇço especÍfica para cintigrafia e conjugados contendo as mesmas
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
HN2008001104A (es) Compuestos para anticuerpos de dickpf-1 y70-4
WO2007087365A8 (en) Detection of glutathionylated proteins
ECSP055635A (es) Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico
WO2005005956A3 (en) Fluorophore compounds and their use in biological systems
GT200300046A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
BRPI0518209A (pt) agentes de ligação especìficos à angiopoietina-2
BRPI0611813A2 (pt) mÉtodo de uso de antagonistas de zonulina para prevenir a perda de ou para regenerar cÉlulas pancreÁticas
ATE304709T1 (de) Substanzen mit verzweigten linkermolekülen
DE60109430D1 (de) An entzündlichen darmerkrankungen beteiligte gene und deren verwendung
ATE467128T1 (de) Kolloidale metallkonjugate
TR200200222T2 (tr) Konjügatların üretimi ve moleküllerin taşınması için kullanımları
WO2005116252A8 (en) Methods for evaluating ribonucleotide sequences
DE602006015629D1 (de) Medizinische vorrichtungen und verfahren zu ihrer herstellung
WO2006133027A3 (en) Methods for immobilizing molecules on surfaces